Clinical Trials Browser

Anemia, Blast Crisis, Burkitt Lymphoma, Graft vs Host Disease, Hodgkin Disease, Leukemia, Leukemia, Megakaryoblastic, Acute, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT02559154 2018-05-04

Modified Bortezomib-based Combination Therapy for Multiple Myeloma

Phase 4 Unknown

80 enrolled

Plasma cell

Multiple Myeloma

NCT01868828 2013-06-06

A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma

Phase 4 Unknown

50 enrolled

Plasma cell

Multiple Myeloma

NCT00652041 2011-09-19

TaCyDexVMP7

Phase 4 Completed

40 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT01249690 2010-11-30

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Phase 4 Unknown

100 enrolled

Plasma cell

Multiple Myeloma

Clinical Trials

BLOOD-dose

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Isa-VRD in TIE HRMM

CHUQUL_HO001

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Plan Development for Giving Teclistamab in the Outpatient Setting

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Home Based Daratumumab Administration for Patients With Multiple Myeloma

VRd MM Fibrate

SCILLA

Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

POMAlternative

Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

IFM-01-04

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

Magnolia

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide

AZABACHE

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

PDD vs PAD to Treat Initially Diagnosed MM

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Modified Bortezomib-based Combination Therapy for Multiple Myeloma

A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma

TaCyDexVMP7

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma